The arrival of a potential new rival in an important product category dinged the share prices of pharmaceutical companies Novo Nordisk (NVO -1.02%) and Eli Lilly (LLY -0.90%) on Tuesday. Both slumped by around 1% on the day, contrasting unfavorably with the slight (0.2%) gain of the benchmark S&P 500 index.Viking invasionThe pharmaceutical star of the day was neither of those two companies. Instead, the spotlight shone on the lesser-known Viking Therapeutics (VKTX 121.02%). On Tuesday, Viking announced that ...

Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions command outrageous prices. Hence, any company creating a new drug to manage it and subsequently get FDA approval results in stock prices soaring faster than SpaceX’s Starship.Suppose you look at some pharmaceutical companies and review how the markets reacted. You might find examples like how the market responded to  ...

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. The success of Novo's bestsellers Ozempic and Wegovy, drugs that help people lose significant amounts of weight, has created something of a gold rush in the pharma industry with about 40 companies developing products that will intensify competition.Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that ha ...

Eli Lilly (LLY 3.18%) has been on a tear this past year, rising up to become the most valuable healthcare stock in the world. It soared past UnitedHealth Group and other top healthcare companies in 2023. Its market cap even pushed past electric vehicle maker Tesla this year. This Indianapolis-based healthcare company has firmly established itself as one of the best and brightest growth stocks around.Let's look at what has investors so excited about this stock, whether investors should worry about its rising ...

Eli Lilly (LLY -1.29%) has become a true behemoth of a healthcare stock, but it lost a bit of bulk on Hump Day. Investors traded out of the shares, and they closed the day more than 1% lower, in contrast to the slight (0.1%) increase of the S&P 500 index. An analyst's recommendation downgrade was quite a factor in that slump.Knocked down a pegWell before market open, DZ Bank's Elmar Kraus knocked his recommendation on Eli Lilly stock down one peg to hold, from his previous buy. In a somewhat counterintuitiv ...

Over the last year, Eli Lilly's (LLY -3.38%) stock is up nearly 120%. This monstrous move has helped propel the pharmaceutical leader to become the largest health care company in the world by market cap. Although Lilly has a number of medications in its portfolio, perhaps its most popular at the moment is Mounjaro. Mounjaro is a glucagon-like peptide-1 (GLP-1) treatment for diabetes patients. It is also the primary competing product to the incredibly popular Ozempic, which was developed by Novo Nordisk.Desp ...

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip cod ...

INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this ...

After a weak start to 2024, Wall Street regained momentum, driven by a solid earnings season, a resilient economy and a technology surge. In fact, the S&P 500 topped the major milestone of 5,000 for the first time ever earlier this month.As such, we have highlighted five stocks from the S&P 500 that have gained more than 25% halfway through the first quarter and have a Zacks Rank #1 (Strong Buy), #2 (Buy), or #3 (Hold). These are Nvidia (NVDA) , Eli Lilly and Company (LLY) , Meta Platforms (META) , Uber Tec ...

With the coveted trillion-dollar valuation, a new pinnacle of success is approaching for a limited number of companies. This once-impossible milestone is now within reach for three formidable potential trillion-dollar stocks. These prominent companies are known for their innovative approaches and rapid expansion. They are nearing a level of financial magnificence previously exclusive to a select few titans.Moreover, this transition highlights a broader story of foresight and resilience. These organizations ...